latest-news-headlines Market Intelligence /marketintelligence/en/news-insights/latest-news-headlines/leveraged-loan-news/leveraged-finance-fights-melanoma-benefit-set-for-may-22-in-nyc content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In This List

Leveraged Finance Fights Melanoma Benefit set for May 22 in NYC

Leveraged Loan Fund Assets Shrink Anew As Retail Investors Eye High Yield

Video: CLOs feel pinch from lumpy loan supply

Retail investors withdraw $2.57B from US high yield bond funds

Despite investor appetite, April European leveraged loan issuance slumps to €2.5B


Leveraged Finance Fights Melanoma Benefit set for May 22 in NYC

The Leveraged Finance Fights Melanoma benefit and cocktail party is planned for Wednesday, May 22, at the Summer Garden at Rockefeller Center. Tickets and sponsorship opportunities are available at the Melanoma Research Alliance (MRA) website.

Funds raised at the event will support the Melanoma Research Alliance (MRA), the world's largest non-profit funder of melanoma research, which was founded in 2007 by Debra and Leon Black under the auspices of the Milken Institute.

Picture from previous fundraiser

Since this event was launched in 2012, the leveraged finance and private equity community has come together and generously supported more than $10.7 million of cutting-edge research to make transforming advances in the prevention, diagnosis and staging, and treatment of melanoma.

The event co-hosts are Clare Bailhe (Apollo|MidCap); Brendan Dillon (UBS); Lee Grinberg (Elliott Management); Christina Minnis (Goldman Sachs); George Mueller (KKR); AJ Murphy (Silver Lake); Geoff Oltmans (Silver Lake); Jeff Rowbottom (PSP Investments); Cade Thompson (KKR); and Trevor Watt (Hellman & Friedman). Attendees include the biggest names in leveraged finance, from all of the top banks, many investment houses, several law firms, select issuers, and some private equity sponsors. As with the prior events, S&P Global Market Intelligence/LCD is a proud sponsor.

Goldman Sachs, Kirkland & Ellis, Latham & Watkins, and Veritas Capital are presenting sponsors. Lead sponsors include Apollo|MidCap, Bloomberg Philanthropies, Fitch Ratings, IHS Markit, and PSP Investments, Simpson Thacher, and UBS. Notable sponsors are Cahill, DavisPolk, Golub Capital, Hellman & Friedman, HPS Investment Partners, Hudson Advisers, KKR, Milbank, New Mountain Finance, Proskauer, Shearman & Sterling, Skadden, Thoma Bravo, Vista Equity Partners, and Weil.

Due to ongoing support from its founders, 100% of donations to MRA directly support research programs working toward a cure for melanoma, the deadliest type of skin cancer. Since MRA began its work, 12 new treatments have been approved by the FDA.

Research performed in the melanoma field continues to have rippling impacts in all of oncology. Treatment approaches and drugs pioneered in melanoma are now approved in many cancers, including: colon, breast, brain, pancreatic, kidney, prostate, bladder, leukemia, lymphoma, and lung cancer.

Tickets are $300. For further information about the event and to purchase tickets, please visit www.curemelanoma.org/lffm. Those seeking information about the event and sponsorship opportunities can contact Janine Rauscher of MRA at (202) 336-8944 or jrauscher@curemelanoma.org.